Prescribing of Proton Pump Inhibitors for Prevention of Upper Gastrointestinal Bleeding in US Outpatient Visits

Antisecretory medications, primarily proton pump inhibitors (PPIs), have proven effective in reducing upper gastrointestinal toxicities, including upper gastrointestinal bleeding (UGIB), associated with nonsteroidal anti-inflammatory drugs (NSAIDs) and aspirin, which are among the most commonly used...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical gastroenterology and hepatology 2024-09, Vol.22 (9), p.1937-1941.e4
Hauptverfasser: Kurlander, Jacob E., Mafi, John N., Racz, Michael J., Barnes, Geoffrey D., Saini, Sameer D., Meek, Patrick D., Tapper, Elliot B., Kullgren, Jeffrey T., Rubenstein, Joel H., Richardson, Caroline R., Helminski, Danielle
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Antisecretory medications, primarily proton pump inhibitors (PPIs), have proven effective in reducing upper gastrointestinal toxicities, including upper gastrointestinal bleeding (UGIB), associated with nonsteroidal anti-inflammatory drugs (NSAIDs) and aspirin, which are among the most commonly used medications in the United States.1 Accordingly, professional guidance recommends PPIs for patients at high risk for UGIB.2–4 However, little is known about trends in use of antisecretory medications for gastrointestinal prophylaxis (“gastroprotection”). Herein, we examined contemporary use and prescribing of antisecretory medications in visits by patients at high risk for UGIB, relative to visits by patients diagnosed with acid-related disorders.
ISSN:1542-3565
1542-7714
1542-7714
DOI:10.1016/j.cgh.2024.01.047